Abbvie’s humira can develop drugs for rare diseases instead of investing all its resources in drugs for common diseases, because it will serve diverse market segments by expanding its commercial value.
HUMIRA (adalimumab) in combination with methotrexate is indicated to reduce the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in pediatric patients over 2 years of age who have had an inadequate response to at least one DMARD.
With this information, we can conclude that HUMIRA is a drug widely used in the world with high resolution.
Learn more about Abbvie’s humira in https://brainly.com/question/23161272